The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review

2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review

December 1, 2013 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

He also highlighted two other studies in adults regarding the treatment of active rheumatoid arthritis (RA), each of which offers important data on challenging questions on the management of RA patients. He noted results of the study by O’Dell and colleagues that showed for the first time the noninferiority of triple therapy compared to etanercept plus methotrexate (MTX) for patients with active RA who don’t respond to MTX alone.2

You Might Also Like
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
Explore This Issue
December 2013
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

According to Chester V. Oddis, MD, professor of medicine and associate director of the rheumatology fellowship training program at the Arthritis Institute in Pittsburgh, who moderated the session, this study offers convincing data that triple therapy produces similar outcomes to biologics, in particular, anti–tumor necrosis factor therapy. “Not only is this an important area from a practice perspective, but it is very important economically, and when payers see this and react to it, then this could greatly affect our choice of treatments for RA,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Another clinical question that is on the minds of many rheumatologists and was addressed in a 2013 published study, said Dr. Wofsy, is whether there is a window of opportunity in early poor prognosis RA that warrants immediate combination therapy. He briefly described a post-hoc analysis of the TEAR trial by O’Dell, Moreland, and colleagues that looked at this a question by randomizing 755 patients with active early RA to immediate combination therapy, MTX plus step up to combination therapy at 24 weeks, or MTX monotherapy.3 At 102 weeks, the study showed comparable clinical and radiographic outcomes between patients treated with initial MTX monotherapy with the option to step up to combination therapy and those treated with initial combination therapy.

Finally, he briefly described a longer follow-up study by Specks and colleagues on remission-inducing regimens for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis.4 The study included 197 patients with severe, organ-threatening ANCA-associated vasculitis randomized to rituximab followed by placebo or cyclophosphamide followed by azathioprine. A 2010 report at six months showed that rituximab was noninferior at six months and superior for relapsing disease. In this updated study, rituximab continued to show noninferiority and superiority at 12 and 18 months. Dr. Wofsy emphasized the importance of the long-term efficacy and sustained response with rituximab shown in the study, as well as the great collaboration among researchers that addressed this challenging problem.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Along with highlighting some of the key studies in adults, he briefly summarized study data on five drugs with new indications—three of which are for pediatrics (See Table 1).

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Drug Updates, Meeting Reports, Rheumatoid Arthritis Tagged With: clinical trials, Disease, Pediatric, review, rheumatology, targeted therapy, TreatmentIssue: December 2013

You Might Also Like:
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
  • 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.